Amylyx Completes Enrollment in Phase 3 Trial for Post-Bariatric Hypoglycemia Drug — Amylyx Pharmaceuticals, Inc.

Event summary

Amylyx has completed enrollment in its Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist targeting post-bariatric hypoglycemia (PBH).
The trial enrolled 78 participants across 21 U.S. sites, with topline data expected in Q3 2026.
Avexitide has FDA Breakthrough Therapy Designation and demonstrated statistically significant reductions in hypoglycemic events in prior trials.
If approved, commercial launch is anticipated for 2027.

The big picture

Amylyx’s completion of the LUCIDITY trial marks a critical step in addressing post-bariatric hypoglycemia, a debilitating condition with no approved treatments. The Phase 3 data will be pivotal in determining whether avexitide can become the first FDA-approved therapy for PBH, potentially unlocking a significant market opportunity. Success could also validate Amylyx’s strategy of targeting rare metabolic disorders with high unmet medical needs.

What we're watching

Regulatory Pathway: Whether the Phase 3 data will support a successful NDA submission and FDA approval for avexitide.
Market Opportunity: The potential commercialization timeline and market penetration of avexitide in treating PBH, a condition affecting ~160,000 U.S. patients.
Competitive Landscape: How Amylyx positions avexitide against emerging therapies for metabolic disorders, particularly those targeting GLP-1 pathways.